MAGE-A3 peptides presented by HLA class II molecules

Details MAGE-A3 peptides presented by HLA class II molecules MAGE-A3 peptides presented by HLA class II molecules

2008-05-13

2008-05-13

Chan, Christina (Department: 1644)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S325000, C435S320100

Reexamination Certificate

active

07371845

ABSTRACT:
The invention describes HLA class II binding peptides encoded by the MAGE-A3 tumor associated gene, as well as nucleic acids encoding such peptides and antibodies relating thereto. The peptides stimulate the activity and proliferation of CD4+T lymphocytes. Methods and products also are provided for diagnosing and treating conditions characterized by expression of the MAGE-A3 gene.

REFERENCES:
patent: 5342774 (1994-08-01), Boon et al.
patent: 5405940 (1995-04-01), Boon et al.
patent: 5585461 (1996-12-01), Townsend et al.
patent: 5591430 (1997-01-01), Townsend et al.
patent: 5965535 (1999-10-01), Chaux et al.
patent: 2351905 (2001-01-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/23031 (1994-10-01), None
patent: WO 95/25740 (1995-09-01), None
patent: WO 97/13858 (1997-04-01), None
patent: WO 98/04582 (1998-02-01), None
patent: WO 99/14326 (1999-03-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 00/20581 (2000-04-01), None
patent: WO 00/52045 (2003-05-01), None
patent: WO 03/040165 (2003-05-01), None
De Plaen et al., “Structure, Chromosomal Localization, and Expression of 12 Genes of the Mage Family,”Immunogeneticsvol. 40 No. 5, pp. 360-369.
Traversari et al.,Immunogenetics35:145-152 (1992).
Van Der Bruggen et al.,Science254:1643-1647 (1991).
Topalian,Curr. Opin. Immunol, 6:741-745 (1994).
Yee et al.,J. Immunol., 157:4079-4086 (1996).
Topalian et al.,J. Exp. Med183:1965-1971 (1996).
Sanderson et al.,Proc. Nat'l. Acad. Sci. USA 92:7217-7221 (1995).
Wu et al.,Proc Nat'l Acad SciUSA 92:11671-11675 (1995).
Gaugler et al.,J. Exp. Med.179:921-930 (1994).
Van Der Bruggen et al.,Eur. J. Immunol.24:3038-3043 (1994).
Herman et al.,Immunogenetics43:377-383 (1996).
Engelhard,Annu. Rev. Immunol., 12:181-207 (1994).
Chicz et al.,J. Exp. Med., 178:27-47 (1993).
Chaux et al., “Identification of Mage-3 Epitopes Presented by H LA-DR Molecules to CD4+ T Lymphocytes,”J. Exp. Med.vol. 189, No. 5, Mar. 1, 1999, pp. 767-777.
Spatola, A.F.,Chem. and Biochem. of Amino Acids, Peptides, and Proteins7:267-357.
Thomson et al.,J. Virol. 72:2246-2252 (1998).
Manici, S. et al., “Melanoma cells present a MAGE-3 epitope to CD4' cytotoxic T cells in association with histocompatibility leukocyte antigen DR11” J. Exp. Med., Mar. 1, 1999, vol. 189, No. 5, pp. 871-876.
Zhang, Y., et al., “A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with MAGE-3 protein.” J. Immunol. Jul. 1, 2003, vol. 171, No. 1, pp. 219-225.
Germain, R.N.,Fundamental Immunolgy, Fourth Edition, W.E. Paul, editor [1999] Lippincott-Raven Press, Philadelphia, pp. 287-340.
Schultz, E.S. et al., “A Mage-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes,”Cancer Res. Nov. 15, 2000, vol. 60, No. 22, pp. 6572-6275.
Reynolds, S.R. et al.,Int. J. Cancer(Sep. 1997) 72(6):972-976.
Smilek, D.E. et al.,Proc. Nat. Acad. Sci. (USA) (Nov. 1991) 88:9633-9637.

Affiliated with

Also associated with

Rating

MAGE-A3 peptides presented by HLA class II molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with MAGE-A3 peptides presented by HLA class II molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAGE-A3 peptides presented by HLA class II molecules will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2790412